New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
07:26 EDTOCR, SIAL, REGN, MRK, BDX, ABBV, WPIGoldman to host a conference
Healthcare CEOs Unscripted Conference is being held in New York on January 3.
News For REGN;WPI;BDX;SIAL;ABBV;MRK;OCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 11, 2014
16:01 EDTMRKOptions Update; November 11, 2014
Subscribe for More Information
15:43 EDTMRKLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
10:20 EDTOCRHigh option volume stocks
High option volume stocks: RLGY TWC LITB SPM ACRX JWN OCR CALL CST ERIC
10:14 EDTREGNRegeneron data reinforce blockbuster potential of dupilumab, says Piper Jaffray
Piper Jaffray believes the Phase IIb results for dupilumab in patients with moderate to severe asthma reported by Regeneron (REGN) and partner Sanofi (SNY) reinforce the broad potential of the drug in a range of allergic diseases. The firm reiterates its $416 price target and Overweight rating on shares of Regeneron.
09:37 EDTMRKActive equity options trading
Subscribe for More Information
09:06 EDTABBVAbbVie announces positive results from chronic hepatitis C patients study
Subscribe for More Information
09:04 EDTABBVEnanta announces results from TURQUOISE-I, CORAL-I studies
Subscribe for More Information
08:13 EDTABBVAbbVie announces positive results from Phase 2b study PEARL-I
Subscribe for More Information
08:11 EDTABBVEnanta announces rseults from Phase 2b PEARL-I study
Subscribe for More Information
08:10 EDTMRKMerck reports results from Phase 2 study of Grazoprevir/Elbasvir
Subscribe for More Information
05:26 EDTREGNRegeneron, Sanofi announce dupilumab Phase 2b study met primary endpoint
Subscribe for More Information
November 10, 2014
14:48 EDTBDXBecton Dickinson management to meet with Jefferies
Meeting to be held on Boston on November 13 hosted by Jefferies.
09:20 EDTMRKOn The Fly: Pre-market Movers
Subscribe for More Information
08:48 EDTMRKGilead rises after Merck presents data on HCV combo
Subscribe for More Information
07:20 EDTMRKGilead overhang from Merck HCV combo removed, says Wells Fargo
Subscribe for More Information
07:19 EDTREGNCredit Suisse to hold a conference
Subscribe for More Information
November 9, 2014
18:58 EDTMRKMerck presents interim data from C-SWIFT study
Merck announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir , the company’s investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide inhibitor for the treatment of chronic hepatitis C virus, HCV, infection. Preliminary findings in treatment-naïve HCV genotype 1- infected non-cirrhotic patients, following six and four weeks of treatment, and patients with cirrhotic disease, following eight and six weeks of treatment, will be presented by Dr. Eric Lawitz, vice president, scientific and research development, The Texas Liver Institute, San Antonio, TX and C-SWIFT lead investigator. This poster presentation is part of a late-breaking abstract session at the 65th American Association for the Study of Liver Diseases, AASLD, Annual Meeting, also known as The Liver Meeting. “These interim data provide a compelling proof-of-concept for the potential of an eight- or six-week triple therapy course in treatment-naive patients with genotype 1 disease, including cirrhotic patients,” said Dr. Lawitz. “These findings will inform the design of larger studies aimed at understanding the potential of short-duration triple therapy across multiple patient types.”
November 7, 2014
10:00 EDTABBVOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:09 EDTABBVAbbVie downgraded to Market Perform at BMO Capital
Subscribe for More Information
06:26 EDTABBVAbbVie downgraded to Market Perform from Outperform at BMO Capital
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use